[go: up one dir, main page]

MX2017016802A - Formulaciones farmaceuticas. - Google Patents

Formulaciones farmaceuticas.

Info

Publication number
MX2017016802A
MX2017016802A MX2017016802A MX2017016802A MX2017016802A MX 2017016802 A MX2017016802 A MX 2017016802A MX 2017016802 A MX2017016802 A MX 2017016802A MX 2017016802 A MX2017016802 A MX 2017016802A MX 2017016802 A MX2017016802 A MX 2017016802A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
pharmaceutically acceptable
acceptable salt
emtncitabine
rilpivirine
Prior art date
Application number
MX2017016802A
Other languages
English (en)
Inventor
Sperger Diana
Koziara Joanna
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2017016802A publication Critical patent/MX2017016802A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona una forma de dosis oral sólida que comprende rilpivirina o una de sus sales farmacéuticamente aceptables, tenofovir alafenamida o una de sus sales farmacéuticamente aceptables, y emtricitabina o una de sus sales farmacéuticamente aceptables.
MX2017016802A 2015-06-30 2016-06-28 Formulaciones farmaceuticas. MX2017016802A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187102P 2015-06-30 2015-06-30
US201662296524P 2016-02-17 2016-02-17
PCT/US2016/039762 WO2017004012A1 (en) 2015-06-30 2016-06-28 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
MX2017016802A true MX2017016802A (es) 2018-09-06

Family

ID=56413867

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016802A MX2017016802A (es) 2015-06-30 2016-06-28 Formulaciones farmaceuticas.

Country Status (16)

Country Link
US (1) US20170027967A1 (es)
EP (1) EP3316869A1 (es)
JP (2) JP2018519325A (es)
KR (2) KR20200037880A (es)
CN (1) CN107921003A (es)
AU (1) AU2016285916B9 (es)
BR (1) BR112017028140A2 (es)
CA (1) CA2921336A1 (es)
EA (1) EA201792591A1 (es)
HK (2) HK1254343A1 (es)
IL (1) IL256491A (es)
MA (1) MA42303A (es)
MX (1) MX2017016802A (es)
NZ (1) NZ738524A (es)
SG (1) SG10201912530XA (es)
WO (1) WO2017004012A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151499A1 (es) 2012-12-21 2015-10-29 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
SI3346995T1 (sl) 2015-11-09 2019-11-29 Gilead Sciences Inc Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
US10835501B2 (en) * 2016-10-01 2020-11-17 Indication Bioscience Llc Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
TW202510891A (zh) 2017-01-31 2025-03-16 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
DK3706762T3 (da) 2017-12-07 2024-12-16 Univ Emory N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil
KR20200135465A (ko) * 2018-03-25 2020-12-02 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. Cgrp 관련 장애를 위한 리메게판트
KR102281373B1 (ko) 2018-04-26 2021-07-22 주식회사 엘지에너지솔루션 고체 전해질 전지용 양극 및 그를 포함하는 고체 전해질 전지
KR102016952B1 (ko) * 2019-04-19 2019-09-02 유니셀랩 주식회사 신규한 결정형 형태의 항바이러스제 및 이의 제조방법
BR112021026916A2 (pt) * 2019-07-03 2022-05-10 Janssen Sciences Ireland Unlimited Co Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina
US20220265689A1 (en) * 2019-07-19 2022-08-25 THE UNITED STATES OF AMERICA , as represented by the Secretary, Department of Health and Human Hiv pre-exposure prophylaxis
CN117338733B (zh) * 2023-10-12 2024-05-28 杭州和泽坤元药业有限公司 一种富马酸替诺福韦二吡呋酯片及其制备工艺
CN119174735A (zh) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 一种含利匹韦林的复方片及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3816A (en) * 2010-11-19 2016-09-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2013116720A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
WO2015022351A1 (en) * 2013-08-14 2015-02-19 Ratiopharm Gmbh Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir

Also Published As

Publication number Publication date
KR20200037880A (ko) 2020-04-09
CN107921003A (zh) 2018-04-17
CA2921336A1 (en) 2016-12-30
AU2016285916B2 (en) 2019-03-07
KR20180048584A (ko) 2018-05-10
NZ738524A (en) 2019-02-22
EP3316869A1 (en) 2018-05-09
WO2017004012A1 (en) 2017-01-05
SG10201912530XA (en) 2020-02-27
HK1252156A1 (zh) 2019-05-17
AU2016285916A1 (en) 2018-01-18
AU2016285916B9 (en) 2019-04-04
US20170027967A1 (en) 2017-02-02
IL256491A (en) 2018-02-28
EA201792591A1 (ru) 2018-06-29
MA42303A (fr) 2018-05-09
HK1254343A1 (zh) 2019-07-19
JP2019116514A (ja) 2019-07-18
JP2018519325A (ja) 2018-07-19
BR112017028140A2 (pt) 2018-08-28

Similar Documents

Publication Publication Date Title
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MX2017016802A (es) Formulaciones farmaceuticas.
IL258464A (en) Pharmaceutical compositions for oral administration of peptide drugs
GB201807942D0 (en) Pharmaceutical formulation
PH12016501841A1 (en) Immunosuppressant formulation
HUP1700253A1 (hu) Szilárd orális gyógyszerkészítmények
SG11202109102PA (en) Pharmaceutical formulations
IL278927A (en) pharmaceutical preparation
ZA202102871B (en) Pharmaceutical formulation
ZA202006570B (en) Pharmaceutical formulations
MX2018005358A (es) Comprimido de dosis alta que contiene mesalazina optimizado.
SG11202010124SA (en) Stable pharmaceutical formulation
PL3326619T3 (pl) Stałe doustne kompozycje farmaceutyczne zawierające tenofowir i emtrycytabinę
SG11202104371XA (en) 1,3,4-oxadiazolone compound and pharmaceutical
EP3723761A4 (en) SOLID ORAL DOSAGE FORM WITH LINAGLIPTIN
PH12018501758A1 (en) Oritavancin formulations
HUE066387T2 (hu) Polimerizált gyógyszert tartalmazó gyógyszerészeti készítmény
IL271908A (en) Over-compressed pharmaceutical preparations
SG11202010792TA (en) Improved pharmaceutical formulations
GB201906473D0 (en) Pharmaceutical formulation
ZA202006346B (en) Pharmaceutical preparation
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
CR20170601A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
TR201721065A2 (tr) Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar
IN2014MU00077A (es)